Clinical Trials Directory

Trials / Unknown

UnknownNCT01071668

Onset of Labor and Metabolomics (GEM-2)

Feasibility Study to Develop the Analysis of the Metabolome During the Onset of Labor During Pregnancy

Status
Unknown
Phase
Study type
Observational
Enrollment
80 (estimated)
Sponsor
Université de Sherbrooke · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

Premature birth is a public health problem and its incidence has recently increased in all developed countries. In Canada, it represented 6.4% of births in 1981 and 7.6% in 2000. In the last decade, the survival rate of premature infants has increased considerably, but neurological vulnerability has not changed. Premature births are the cause of approximately 28% of neonatal mortality in the world and is the major cause of perinatal mortality and morbidity in developed countries. Approximately 75-80% of preterm births are spontaneous preterm birth. This type of premature birth included the preterm labor and premature rupture of membranes before term. The contractile activity represents one of the fundamental properties of the uterus during pregnancy and childbirth. The abnormalities associated with uterine contractions are the cause of pathological conditions with important consequences for the mother and fetus. Metabolomics involves a new technology to investigate small molecules that characterize biochemical pathways of interest. The change in concentration levels of these molecules in various biological samples such as urine and blood in the presence of a disease or a patient can be particularly useful for identifying new biomarkers. The hypothesis of this study is that gestational metabolomes detected in maternal fluids differ according to pathological situations and lead to the initiation of spontaneous labor. The whole research program has two complementary objectives in order to expect a decrease of prematurity: a) better understanding of all the physiological mechanisms leading to prematurity and b) better identification of patients at high risk for a better management of these women.

Detailed description

Metabolomics involves a new technology using the methods of separation and detection complex to investigate a set of small molecules that characterize biochemical pathways of interest. The change in concentration levels of these molecules in various biological samples such as urine and blood in the presence of a disease or a patient can detect metabolic fingerprints that can be particularly useful for identifying new biomarkers. These will thereafter be quantified and validated by metabolic profiling. To our knowledge, there are few studies on metabolomics and pregnancy. Methods: The studied population will be pregnant women between 20-30 weeks of gestation without any obstetrical complications. Vaginal secretions, blood and urine samples will be taken: * After inclusion in the project * At hospital admission for delivery * During labor Blood and urine sample will also be taken: * 48 hours after delivery * 6-8 weeks after delivery

Conditions

Timeline

Start date
2009-04-01
Primary completion
2017-03-01
Completion
2017-06-01
First posted
2010-02-19
Last updated
2015-05-12

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT01071668. Inclusion in this directory is not an endorsement.